iSpecimen Delays 10-Q Filing for Q1 2025

iSpecimen ( (ISPC) ) has released a notification of late filing.

iSpecimen Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending March 31, 2025. The company cites that the report could not be filed within the prescribed 40-day period without incurring unreasonable effort or expense. As a result, iSpecimen is utilizing the five-day extension period allowed under Rule 12b-25. The company anticipates filing the report within this extension timeframe. Importantly, iSpecimen does not expect any significant changes in its financial results compared to the corresponding period of the previous fiscal year. However, the report includes forward-looking statements that involve risks and uncertainties, which are subject to change. The notification was signed by Robert Bradley Lim, the Chief Executive Officer, indicating the company’s commitment to ongoing compliance efforts.

Spark’s Take on ISPC Stock

According to Spark, TipRanks’ AI Analyst, ISPC is a Underperform.

iSpecimen’s overall stock score is low due to significant financial performance issues, including declining revenues and negative cash flows. The bearish technical indicators also contribute to the negative outlook. Additionally, the lack of profitability and dividend yield severely impacts the stock’s valuation. Strategic interventions are necessary to address these challenges and improve the company’s financial health.

To see Spark’s full report on ISPC stock, click here.

More about iSpecimen

Average Trading Volume: 512,235

Technical Sentiment Signal: Sell

Current Market Cap: $2.95M

See more data about ISPC stock on TipRanks’ Stock Analysis page.